CA2904020C - Improved methods for conducting multiplexed assays - Google Patents
Improved methods for conducting multiplexed assays Download PDFInfo
- Publication number
- CA2904020C CA2904020C CA2904020A CA2904020A CA2904020C CA 2904020 C CA2904020 C CA 2904020C CA 2904020 A CA2904020 A CA 2904020A CA 2904020 A CA2904020 A CA 2904020A CA 2904020 C CA2904020 C CA 2904020C
- Authority
- CA
- Canada
- Prior art keywords
- binding
- seq
- targeting
- analyte
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 152
- 238000003556 assay Methods 0.000 title abstract description 121
- 239000012491 analyte Substances 0.000 claims abstract description 215
- 230000009871 nonspecific binding Effects 0.000 claims abstract description 23
- 238000000159 protein binding assay Methods 0.000 claims abstract description 21
- 230000003993 interaction Effects 0.000 claims abstract description 16
- 238000009739 binding Methods 0.000 claims description 898
- 230000027455 binding Effects 0.000 claims description 892
- 239000003795 chemical substances by application Substances 0.000 claims description 753
- 239000003153 chemical reaction reagent Substances 0.000 claims description 537
- 230000008685 targeting Effects 0.000 claims description 532
- 230000000295 complement effect Effects 0.000 claims description 296
- 108091034117 Oligonucleotide Proteins 0.000 claims description 294
- 230000000153 supplemental effect Effects 0.000 claims description 117
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 113
- 238000001514 detection method Methods 0.000 claims description 90
- 108010090804 Streptavidin Proteins 0.000 claims description 59
- 229960002685 biotin Drugs 0.000 claims description 59
- 239000011616 biotin Substances 0.000 claims description 59
- 235000020958 biotin Nutrition 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 47
- 230000009260 cross reactivity Effects 0.000 claims description 43
- 108090001008 Avidin Proteins 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 20
- 239000011859 microparticle Substances 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 238000005259 measurement Methods 0.000 claims description 14
- 230000002788 anti-peptide Effects 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 10
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 9
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical group NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 9
- 108091023037 Aptamer Proteins 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 8
- 238000000149 argon plasma sintering Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 150000001540 azides Chemical class 0.000 claims description 7
- 150000001345 alkine derivatives Chemical class 0.000 claims description 6
- 230000005389 magnetism Effects 0.000 claims description 5
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 238000012875 competitive assay Methods 0.000 claims description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 2
- 238000012493 sandwich binding assay Methods 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000007790 solid phase Substances 0.000 abstract description 16
- 239000000523 sample Substances 0.000 description 93
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 89
- 238000006243 chemical reaction Methods 0.000 description 33
- YBJHBAHKTGYVGT-ZXFLCMHBSA-N 5-[(3ar,4r,6as)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@H]2[C@@H](CCCCC(=O)O)SC[C@H]21 YBJHBAHKTGYVGT-ZXFLCMHBSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 24
- 239000003085 diluting agent Substances 0.000 description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 21
- 238000002820 assay format Methods 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- 150000003573 thiols Chemical class 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 13
- -1 hydrazide group Chemical group 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 238000002966 oligonucleotide array Methods 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 102100031013 Transgelin Human genes 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012898 sample dilution Substances 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002967 competitive immunoassay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 125000002355 alkine group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BZSVVCFHMVMYCR-UHFFFAOYSA-N 2-pyridin-2-ylpyridine;ruthenium Chemical compound [Ru].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1 BZSVVCFHMVMYCR-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- NGNQZCDZXSOVQU-UHFFFAOYSA-N 8,16,18,26,34,36-hexahydroxyhentetracontane-2,6,10,14,24,28,32-heptone Chemical compound CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCC(C)=O NGNQZCDZXSOVQU-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101150045895 Apela gene Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003154 D dimer Chemical group 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- DRSFVGQMPYTGJY-GNSLJVCWSA-N Deprodone propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DRSFVGQMPYTGJY-GNSLJVCWSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Chemical group 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 101100177665 Rattus norvegicus Hipk3 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 241001279361 Stachybotrys Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241001264154 Verticimonosporium Species 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 241000353223 Xenopsylla cheopis Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 108010072035 antithrombin III-protease complex Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108010052295 fibrin fragment D Chemical group 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000012923 label-free technique Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010897 surface acoustic wave method Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50853—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates with covers or lids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/021—Identification, e.g. bar codes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/043—Hinged closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0609—Holders integrated in container to position an object
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Clinical Laboratory Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3153763A CA3153763A1 (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775860P | 2013-03-11 | 2013-03-11 | |
| US61/775,860 | 2013-03-11 | ||
| US201361778727P | 2013-03-13 | 2013-03-13 | |
| US61/778,727 | 2013-03-13 | ||
| PCT/US2014/022948 WO2014164594A1 (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153763A Division CA3153763A1 (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2904020A1 CA2904020A1 (en) | 2014-10-09 |
| CA2904020C true CA2904020C (en) | 2022-06-14 |
Family
ID=51488514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2904020A Active CA2904020C (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
| CA3153763A Pending CA3153763A1 (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153763A Pending CA3153763A1 (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
Country Status (10)
| Country | Link |
|---|---|
| US (13) | US10189023B2 (enExample) |
| EP (2) | EP4219750A3 (enExample) |
| JP (1) | JP6791750B2 (enExample) |
| KR (4) | KR102275006B1 (enExample) |
| CN (2) | CN110286215A (enExample) |
| AU (3) | AU2014249190C1 (enExample) |
| CA (2) | CA2904020C (enExample) |
| DK (1) | DK2972353T3 (enExample) |
| ES (1) | ES2942031T3 (enExample) |
| WO (1) | WO2014164594A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102275006B1 (ko) | 2013-03-11 | 2021-07-09 | 메소 스케일 테크놀러지즈, 엘엘시 | 다중화 어세이를 수행하기 위한 개선된 방법 |
| US9618510B2 (en) | 2013-03-13 | 2017-04-11 | Meso Scale Technologies, Llc. | Assay methods |
| EP3027773B1 (en) | 2013-07-30 | 2020-03-25 | President and Fellows of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
| AU2015259048B2 (en) | 2014-05-15 | 2021-09-09 | Meso Scale Technologies, Llc. | Improved assay methods |
| CA3129007A1 (en) | 2015-04-06 | 2016-10-13 | Eli N. Glezer | High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus |
| SG11201708429WA (en) * | 2015-04-22 | 2017-11-29 | Berkeley Lights Inc | Microfluidic cell culture |
| EP3322533A4 (en) | 2015-07-15 | 2019-03-20 | Hycor Biomedical, LLC | PERSONALIZABLE INSTRUMENT |
| KR102557419B1 (ko) * | 2015-08-07 | 2023-07-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 단백질-단백질 상호작용의 초해상도 영상화 |
| US10799865B2 (en) | 2015-10-27 | 2020-10-13 | Berkeley Lights, Inc. | Microfluidic apparatus having an optimized electrowetting surface and related systems and methods |
| USD882818S1 (en) * | 2016-03-18 | 2020-04-28 | Meso Scale Technologies, Llc. | Reagent rack |
| USD1006251S1 (en) * | 2016-03-18 | 2023-11-28 | Meso Scale Technologies, Llc. | Rack and label |
| USD889685S1 (en) * | 2016-03-18 | 2020-07-07 | Meso Scale Technologies, Llc. | Reagent rack cover |
| SG10202008265XA (en) | 2016-05-26 | 2020-09-29 | Berkeley Lights Inc | Covalently modified surfaces, kits, and methods of preparation and use |
| US10809266B2 (en) * | 2016-07-22 | 2020-10-20 | Verily Life Sciences Llc | Quantitative massively parallel proteomics |
| WO2018025046A2 (en) * | 2016-08-05 | 2018-02-08 | Nn Scientific Limited | Device |
| US10618717B2 (en) * | 2017-07-31 | 2020-04-14 | Argos Technology, Inc. | Cryogenic storage box |
| WO2019069372A1 (ja) * | 2017-10-03 | 2019-04-11 | 株式会社ニコン | 検出対象の測定方法、捕捉プローブ固定化担体、検出キット、及び流体デバイス |
| EP4372383A3 (en) * | 2017-10-23 | 2024-11-06 | Nautilus Subsidiary, Inc. | Methods and systems for protein identification |
| EA202091646A1 (ru) * | 2018-01-05 | 2020-11-17 | Квошент Сюисс Са | Платформа на основе самособирающегося диагностического массива |
| FI3756009T3 (fi) | 2018-02-23 | 2023-12-01 | Meso Scale Technologies Llc | Menetelmiä antigeeniä sitovien molekyylien seulontaan normalisoimalla antigeeniä sitovan molekyylin pitoisuus |
| US11039856B2 (en) | 2018-05-10 | 2021-06-22 | Verily Life Sciences Llc | Surgical laparoscopic ports for implanting medical systems |
| WO2019222708A2 (en) | 2018-05-17 | 2019-11-21 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| WO2020018592A1 (en) | 2018-07-17 | 2020-01-23 | Methodical Mind, Llc. | Graphical user interface system |
| WO2020086751A1 (en) | 2018-10-23 | 2020-04-30 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| CN113039287B (zh) * | 2018-11-16 | 2024-08-13 | 豪夫迈·罗氏有限公司 | 具有结合对的成员的涂覆有链霉亲和素的固相 |
| CN113227790A (zh) | 2018-11-19 | 2021-08-06 | 拜尔阿斯特公司 | 用于多重结合实验的方法及试剂 |
| GB2579810B (en) * | 2018-12-14 | 2023-04-26 | Aeirtec Ltd | Assay Analysis |
| EP3931201A1 (en) | 2019-03-01 | 2022-01-05 | Meso Scale Technologies, LLC | Electrochemiluminescent labeled probes for use in immunoassay methods, methods using such and kits comprising same |
| EP3963100A1 (en) | 2019-05-03 | 2022-03-09 | Meso Scale Technologies, LLC | Kits for detecting one or more target nucleic acid analytes in a sample and methods of making and using the same |
| WO2021092004A1 (en) | 2019-11-05 | 2021-05-14 | Meso Scale Technologies, Llc. | Methods and kits for quantitating radiation exposure |
| US20230021837A1 (en) | 2019-11-26 | 2023-01-26 | Meso Scale Technologies, Llc. | Methods and kits for detecting autoimmune diseases |
| WO2021222827A1 (en) | 2020-05-01 | 2021-11-04 | Meso Scale Technologies, Llc. | Methods and kits for virus detection |
| EP4182687A4 (en) * | 2020-07-20 | 2024-09-11 | Bio-Rad Laboratories, Inc. | IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR |
| EP4121557A4 (en) | 2020-08-06 | 2024-05-01 | Singular Genomics Systems, Inc. | Spatial sequencing |
| US11492662B2 (en) | 2020-08-06 | 2022-11-08 | Singular Genomics Systems, Inc. | Methods for in situ transcriptomics and proteomics |
| JP2023539360A (ja) | 2020-09-02 | 2023-09-13 | メソ スケール テクノロジーズ エルエルシー | サンプル中の１つ以上の標的分析物を検出するためのキット並びにそれを作製及び使用する方法 |
| WO2022051481A2 (en) | 2020-09-04 | 2022-03-10 | Meso Scale Technologies, Llc. | Methods for isolating central nervous system surface marker displaying agents |
| CA3207187A1 (en) | 2021-01-11 | 2022-07-14 | Meso Scale Technologies, Llc. | Assay system calibration systems and methods |
| EP4302089A1 (en) | 2021-03-01 | 2024-01-10 | Meso Scale Technologies, LLC | System and method for conducting a multiplexed assay |
| WO2022231900A1 (en) | 2021-04-26 | 2022-11-03 | Meso Scale Technologies, Llc. | Methods for isolating and analyzing a target analyte encapsulated by a surface marker displaying agent |
| WO2022235764A1 (en) | 2021-05-05 | 2022-11-10 | Singular Genomics Systems, Inc. | Multiomic analysis device and methods of use thereof |
| WO2022246213A1 (en) | 2021-05-21 | 2022-11-24 | Meso Scale Techologies, Llc. | Assays for viral strain determination |
| AU2022304570A1 (en) | 2021-06-28 | 2024-01-18 | Meso Scale Technologies, Llc. | Methods, compositions, and kits for assay signal amplification |
| AU2022316208A1 (en) | 2021-07-21 | 2024-02-01 | Methodical Mind, Llc. | Graphical user interface system guide module |
| EP4540610A1 (en) | 2022-06-17 | 2025-04-23 | Meso Scale Technologies, LLC | Viral strain serology assays |
| US20240103002A1 (en) | 2022-09-23 | 2024-03-28 | Meso Scale Technologies, Llc. | Orthopoxvirus serology assays |
| US20240229110A1 (en) | 2022-12-20 | 2024-07-11 | Meso Scale Technologies, Llc. | Assay methods and kits |
| IL321956A (en) | 2023-01-09 | 2025-09-01 | Methodical Mind Llc | Graphical user interface system for quality control |
| WO2024158937A1 (en) | 2023-01-25 | 2024-08-02 | Methodical Mind, Llc | Laboratory coordination devices, methods, and systems |
| WO2024242845A1 (en) | 2023-05-24 | 2024-11-28 | Meso Scale Technologies, Llc. | Methods for assessing colorectal cancer using extracellular vesicles |
| WO2024249961A1 (en) | 2023-06-01 | 2024-12-05 | Singular Genomics Systems, Inc. | Methods and probes for detecting polynucleotide sequences in cells and tissues |
| WO2025049305A1 (en) | 2023-08-25 | 2025-03-06 | Meso Scale Technologies, Llc. | Viral strain serology assays |
| WO2025188949A1 (en) | 2024-03-08 | 2025-09-12 | Meso Scale Technologies, Llc. | Methods of quantifying analytes |
| WO2025260043A1 (en) | 2024-06-14 | 2025-12-18 | Meso Scale Technologies, Llc. | Methods and kits for measuring three or more tau epitopes |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4161515A (en) | 1973-10-02 | 1979-07-17 | Syva Company | Double receptor fluorescent immunoassay |
| US4604263A (en) * | 1976-06-17 | 1986-08-05 | Analytical Products, Inc. | Cell for gas sample equilibrator |
| US4139346A (en) | 1977-11-28 | 1979-02-13 | Enzo Bio Chem Incorporated | Nucleic acid and protein binding paper |
| FI56750C (fi) | 1978-02-27 | 1980-03-10 | Reijo Vihko | Rekationskaerl foer engaongsbruk vid immunologiskt bestaemning |
| IL55816A (en) | 1978-10-30 | 1982-04-30 | Ames Yissum Ltd | Method for simultaneous immunoassay of several different antibodies and a kit therefor |
| US4378344A (en) | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
| US4514508A (en) | 1982-07-06 | 1985-04-30 | Biond Inc. | Assaying for a multiplicity of antigens or antibodies with a detection compound |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| AU3844485A (en) | 1984-02-09 | 1985-08-15 | Enzo Biochem Inc. | Heterologous detection of cabeled dna |
| US4748111A (en) | 1984-03-12 | 1988-05-31 | Molecular Diagnostics, Inc. | Nucleic acid-protein conjugate used in immunoassay |
| US5288609A (en) | 1984-04-27 | 1994-02-22 | Enzo Diagnostics, Inc. | Capture sandwich hybridization method and composition |
| CA1260372A (en) | 1984-04-27 | 1989-09-26 | Elazar Rabbani | Hybridization method for the detection of genetic materials |
| US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| JPH0823558B2 (ja) | 1984-11-27 | 1996-03-06 | オ−ジエニクス リミテツド | 検定装置 |
| JPH076984B2 (ja) | 1985-05-31 | 1995-01-30 | 株式会社日立製作所 | 複数項目分析方法 |
| US6165729A (en) | 1986-04-30 | 2000-12-26 | Hyperion Catalysis International, Inc. | Electrochemiluminescent reaction utilizing amine-derived reductant |
| US5147806A (en) | 1988-04-29 | 1992-09-15 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescence measurements |
| US5591581A (en) | 1986-04-30 | 1997-01-07 | Igen, Inc. | Electrochemiluminescent rhenium moieties and methods for their use |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| US5750338A (en) | 1986-10-23 | 1998-05-12 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
| US4870003A (en) | 1987-06-15 | 1989-09-26 | Coulter Corporation | Simultaneous enzyme immunoassay for detecting antigen and/or antibody in humans |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| US5308754A (en) | 1988-03-21 | 1994-05-03 | Kankare Jouko J | Electrogenerated luminescence in solution |
| US5354655A (en) | 1988-03-29 | 1994-10-11 | Biocontrol Systems, Inc. | Method for determining the presence or concentration of a bound enzyme |
| US5093268A (en) | 1988-04-28 | 1992-03-03 | Igen, Inc. | Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena |
| US5705402A (en) | 1988-11-03 | 1998-01-06 | Igen International, Inc. | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| US6448091B1 (en) | 1988-11-03 | 2002-09-10 | Igen International, Inc. | Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection |
| CA2049036A1 (en) | 1989-03-21 | 1990-09-22 | Izak Bahar | Simultaneous dual analyte assay |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6406844B1 (en) | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| CA2022518A1 (en) | 1989-08-04 | 1991-02-05 | Richard P. Watts | Heterogeneous binding assays |
| US5719063A (en) | 1989-08-25 | 1998-02-17 | Boehringer Mannheim Corporation | Multiplex immunoassay system |
| US5324457A (en) | 1989-10-02 | 1994-06-28 | Board Of Regents, The University Of Tx System | Devices and methods for generating electrogenerated chemiluminescence |
| US5629153A (en) | 1990-01-10 | 1997-05-13 | Chiron Corporation | Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
| EP0515370B1 (en) | 1990-02-22 | 1995-03-01 | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING (McGILL UNIVERSITY) | A solid-phase interferometric immunoassay system |
| US5143852A (en) | 1990-09-14 | 1992-09-01 | Biosite Diagnostics, Inc. | Antibodies to ligand analogues and their utility in ligand-receptor assays |
| US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
| US5726064A (en) | 1990-11-22 | 1998-03-10 | Applied Research Systems Ars Holding Nv | Method of assay having calibration within the assay |
| ZA92803B (en) | 1991-02-06 | 1992-11-25 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescene asay including plurality of magnets |
| JPH0534345A (ja) | 1991-02-19 | 1993-02-09 | Tdk Corp | 化学発光を利用する抗原・抗体の測定方法 |
| US5877028A (en) | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
| US5665539A (en) | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
| JPH06509417A (ja) | 1991-07-16 | 1994-10-20 | トランスメッド バイオテック インコーポレイテッド | 多重検体の同時分析の方法と構成 |
| ES2097925T3 (es) | 1991-09-18 | 1997-04-16 | Affymax Tech Nv | Metodo para sintetizar diversas colecciones de oligomeros. |
| US5516635A (en) | 1991-10-15 | 1996-05-14 | Ekins; Roger P. | Binding assay employing labelled reagent |
| ZA929351B (en) | 1991-12-11 | 1993-06-04 | Igen Inc | Electrochemiluminescent label for DNA assays. |
| US5464746A (en) | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| US5518887A (en) | 1992-03-30 | 1996-05-21 | Abbott Laboratories | Immunoassays empolying generic anti-hapten antibodies and materials for use therein |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5795714A (en) | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
| US6087491A (en) * | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
| IT1270951B (it) | 1993-06-07 | 1997-05-26 | Boehringer Mannheim Italia | Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| CA2170264A1 (en) * | 1993-09-10 | 1995-03-16 | Michael W. Konrad | Optical detection of position of oligonucleotides on large dna molecules |
| US5415839A (en) | 1993-10-21 | 1995-05-16 | Abbott Laboratories | Apparatus and method for amplifying and detecting target nucleic acids |
| US5561043A (en) | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
| US7569341B2 (en) | 1994-01-31 | 2009-08-04 | Trustees Of Boston University | Nucleic acid directed immobilization arrays and methods of assembly |
| US5786141A (en) | 1994-08-26 | 1998-07-28 | Bard; Allen J. | Electrogenerated chemiluminescence labels for analysis and/or referencing |
| US5648213A (en) | 1994-08-30 | 1997-07-15 | Beckman Instruments, Inc. | Compositions and methods for use in detection of analytes |
| US5620850A (en) | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
| US5866434A (en) | 1994-12-08 | 1999-02-02 | Meso Scale Technology | Graphitic nanotubes in luminescence assays |
| US5641623A (en) | 1995-01-04 | 1997-06-24 | Martin; Mark T. | Electrochemiluminescence assay |
| US5643713A (en) | 1995-06-07 | 1997-07-01 | Liang; Pam | Electrochemiluminescent monitoring of compounds |
| US6207369B1 (en) | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
| CZ299135B6 (cs) | 1995-03-10 | 2008-04-30 | Meso Scale Technologies, Llc. Corporation Servicecompany | Kazeta a zarízení pro použití pri detekci analytu, zpusob provádení testu za použití uvedené kazety, kit pro použití pri provádení množiny elektrochemiluminescencních testu a zpusob detekce nebo merení analytu |
| US5722553A (en) * | 1995-03-31 | 1998-03-03 | Hovatter; Kenneth P. | Integral assembly of microcentrifuge strip tubes having independently tethered angularly related seal caps |
| US6319670B1 (en) | 1995-05-09 | 2001-11-20 | Meso Scale Technology Llp | Methods and apparatus for improved luminescence assays using microparticles |
| US5679519A (en) | 1995-05-09 | 1997-10-21 | Oprandy; John J. | Multi-label complex for enhanced sensitivity in electrochemiluminescence assay |
| US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
| US5723320A (en) | 1995-08-29 | 1998-03-03 | Dehlinger; Peter J. | Position-addressable polynucleotide arrays |
| DE69638321D1 (de) | 1995-10-11 | 2011-03-03 | Luminex Corp | Gleichzeitige mehrfachanalyse klinischer proben |
| GB9606850D0 (en) | 1996-04-01 | 1996-06-05 | Univ Liverpool | An assay system and novel labelled compounds for use therwith |
| US6001310A (en) * | 1996-10-11 | 1999-12-14 | Shaffer; John V. | Pliable centrifuge tube array |
| EP0943013A2 (en) * | 1996-12-06 | 1999-09-22 | Niels Pallisgaard | Detection of chromosomal abnormalities |
| FR2764381A1 (fr) | 1997-06-09 | 1998-12-11 | Univ De Neuchatel | Detecteur electrochimioluminescent |
| US6413783B1 (en) | 1997-09-18 | 2002-07-02 | Meso Scale Technologies, Llc | Assay sonication apparatus and methodology |
| US6200531B1 (en) | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
| EP0962773A1 (en) | 1998-06-03 | 1999-12-08 | Mark Howard Jones | Electrochemical based assay processes instrument and labels |
| GB9815042D0 (en) | 1998-07-10 | 1998-09-09 | Imperial College | Detector |
| US6214552B1 (en) | 1998-09-17 | 2001-04-10 | Igen International, Inc. | Assays for measuring nucleic acid damaging activities |
| US6541203B2 (en) * | 1998-11-23 | 2003-04-01 | President And Fellows Of Harvard College | Detecting structural or synthetic information about chemical compounds |
| US6136268A (en) | 1999-08-17 | 2000-10-24 | Orion Diagnostica | Method for luminescence measurements |
| US20050287592A1 (en) * | 2000-08-29 | 2005-12-29 | Yeda Research And Development Co. Ltd. | Template-dependent nucleic acid polymerization using oligonucleotide triphosphates building blocks |
| US7070740B1 (en) | 2000-09-28 | 2006-07-04 | Beckman Coulter, Inc. | Method and apparatus for processing biomolecule arrays |
| US6601725B2 (en) * | 2001-05-15 | 2003-08-05 | 3088081 Canada, Inc. | Integral assembly of reagent tubes and seal caps |
| DK2461156T3 (da) | 2001-06-29 | 2020-08-03 | Meso Scale Technologies Llc | Indretning til luminescenstestmålinger |
| US6942972B2 (en) | 2001-10-24 | 2005-09-13 | Beckman Coulter, Inc. | Efficient synthesis of protein-oligonucleotide conjugates |
| CA2495881C (en) * | 2002-08-19 | 2014-07-08 | The President And Fellows Of Harvard College | Evolving new molecular function |
| US20040049351A1 (en) * | 2002-08-28 | 2004-03-11 | Matson Robert S. | Immunosorbent assay in microarray format |
| US6913890B2 (en) * | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
| US7229763B2 (en) | 2003-04-07 | 2007-06-12 | Beckman Coulter, Inc. | Assay system using labeled oligonucleotides |
| US7195875B2 (en) | 2003-04-18 | 2007-03-27 | Beckman Coulter, Inc. | Oligonucleotide pairs for multiplexed binding assays |
| US20040258563A1 (en) * | 2003-06-23 | 2004-12-23 | Applera Corporation | Caps for sample wells and microcards for biological materials |
| JP2005164509A (ja) * | 2003-12-05 | 2005-06-23 | Hitachi High-Technologies Corp | 試薬容器 |
| WO2005059509A2 (en) * | 2003-12-12 | 2005-06-30 | Saint Louis University | Biosensors for detecting macromolecules and other analytes |
| EP1774033A4 (en) | 2004-06-10 | 2008-04-23 | Perkinelmer Las Inc | MULTIPLEX ASSAYS FOR DETECTION OF ANALYTES |
| US7704730B2 (en) | 2004-10-14 | 2010-04-27 | Meso Scale Technologies, Llc | Multiplexed assay methods |
| US20060292559A1 (en) | 2005-06-23 | 2006-12-28 | Beckman Coulter, Inc. | Cell-based microarrays, and methods for their preparation and use |
| US7494776B2 (en) | 2005-07-07 | 2009-02-24 | Beckman Coulter, Inc. | Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands |
| KR100927886B1 (ko) | 2007-06-18 | 2009-11-23 | 한국생명공학연구원 | 단백질 ｇ-올리고 뉴클레오타이드 결합체 |
| EP3222733B1 (en) * | 2007-07-13 | 2021-04-07 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
| WO2009012343A2 (en) | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Arrays, substrates, devices, methods and systems for detecting target molecules |
| CA2730565A1 (en) * | 2007-07-27 | 2009-02-05 | Ensemble Discovery Corporation | Detection assays and use thereof |
| EP2088204A1 (en) | 2008-02-05 | 2009-08-12 | Adnagen AG | Method and kit for diagnosing or controlling the treatment of ovarian cancer |
| JP2011527903A (ja) | 2008-07-14 | 2011-11-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 細胞マイクロキャリアのアセンブリを供給するためのプロセス |
| CA2647953A1 (en) * | 2008-12-29 | 2010-06-29 | Sqi Diagnostics Systems Inc. | Multiplex analyte detection |
| US20100261292A1 (en) | 2009-04-10 | 2010-10-14 | Meso Scale Technologies, Llc | Methods for Conducting Assays |
| US8480953B2 (en) * | 2009-05-20 | 2013-07-09 | Protedyne Corporation | System and method for vessel alignment |
| US20130035259A1 (en) * | 2010-11-22 | 2013-02-07 | The University Of Chicago | Methods and/or Systems Producing and Providing Sets of Oligonucleotide Conjugates for Assays and Detections |
| US9182334B2 (en) * | 2012-02-24 | 2015-11-10 | Agilent Technologies, Inc. | Method of determining thermodynamic and kinetic parameters from measured off rates |
| JP5926990B2 (ja) * | 2012-03-16 | 2016-05-25 | シスメックス株式会社 | 検体処理装置 |
| US9180461B2 (en) * | 2012-10-22 | 2015-11-10 | Qiagen Gaithersburg, Inc. | Condensation-reducing incubation cover |
| USD703345S1 (en) * | 2012-10-29 | 2014-04-22 | Universal Bio Research Co., Ltd. | Plurality of reaction vessels with lids |
| CN105263627B (zh) * | 2013-01-18 | 2019-05-21 | 生米公司 | 分析设备 |
| KR102275006B1 (ko) * | 2013-03-11 | 2021-07-09 | 메소 스케일 테크놀러지즈, 엘엘시 | 다중화 어세이를 수행하기 위한 개선된 방법 |
| US9802196B2 (en) * | 2013-03-13 | 2017-10-31 | Alphagem Bio Inc. | Ergonomic numbered connector to hold tubes with improved cap |
| US8808650B1 (en) * | 2013-03-15 | 2014-08-19 | Shazi Iqbal | Foldable specimen rack with configurable specimen receiver |
| BR112015022459B1 (pt) * | 2013-03-15 | 2021-10-19 | Becton, Dickinson And Company | Sistema de tubo de processamento e de bandeja transportadora |
| EP3027773B1 (en) * | 2013-07-30 | 2020-03-25 | President and Fellows of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
-
2014
- 2014-03-11 KR KR1020157028300A patent/KR102275006B1/ko active Active
- 2014-03-11 KR KR1020227036862A patent/KR102746751B1/ko active Active
- 2014-03-11 AU AU2014249190A patent/AU2014249190C1/en active Active
- 2014-03-11 EP EP23157850.1A patent/EP4219750A3/en active Pending
- 2014-03-11 US US14/203,638 patent/US10189023B2/en active Active
- 2014-03-11 JP JP2016501106A patent/JP6791750B2/ja active Active
- 2014-03-11 DK DK14778374.0T patent/DK2972353T3/da active
- 2014-03-11 WO PCT/US2014/022948 patent/WO2014164594A1/en not_active Ceased
- 2014-03-11 CA CA2904020A patent/CA2904020C/en active Active
- 2014-03-11 KR KR1020217020789A patent/KR102459433B1/ko active Active
- 2014-03-11 EP EP14778374.0A patent/EP2972353B1/en active Active
- 2014-03-11 KR KR1020247042210A patent/KR20250002843A/ko active Pending
- 2014-03-11 CA CA3153763A patent/CA3153763A1/en active Pending
- 2014-03-11 CN CN201910389701.1A patent/CN110286215A/zh active Pending
- 2014-03-11 CN CN201480026770.1A patent/CN105378477B9/zh active Active
- 2014-03-11 ES ES14778374T patent/ES2942031T3/es active Active
-
2015
- 2015-09-08 US US14/847,381 patent/US10413904B2/en active Active
- 2015-09-08 US US14/847,761 patent/US20160069872A1/en not_active Abandoned
-
2017
- 2017-10-16 US US15/784,399 patent/US10201812B2/en not_active Ceased
-
2018
- 2018-12-05 US US16/210,165 patent/US11148145B2/en active Active
- 2018-12-20 US US16/227,081 patent/US11059046B2/en active Active
-
2019
- 2019-09-13 US US16/570,309 patent/US11772098B2/en active Active
-
2020
- 2020-01-30 AU AU2020200675A patent/AU2020200675B2/en active Active
-
2021
- 2021-02-11 US US17/173,898 patent/USRE49774E1/en active Active
- 2021-03-29 US US17/215,962 patent/US11951483B2/en active Active
- 2021-09-16 US US17/476,880 patent/US20210402390A1/en active Pending
-
2022
- 2022-09-19 AU AU2022233771A patent/AU2022233771A1/en active Pending
-
2023
- 2023-08-24 US US18/237,677 patent/US12343726B2/en active Active
-
2024
- 2024-03-06 US US18/597,358 patent/US20240375109A1/en active Pending
-
2025
- 2025-05-28 US US19/220,283 patent/US20250375769A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020200675B2 (en) | Improved methods for conducting multiplexed assays | |
| US12359264B2 (en) | Co-binder assisted assay methods | |
| HK1213048B (en) | Improved methods for conducting multiplexed assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190307 |
|
| EEER | Examination request |
Effective date: 20190307 |